SHR-3167

SHR-3167 is an investigational drug developed by Jiangsu Hengrui Pharmaceuticals for the treatment of type 2 diabetes. It is currently in Phase 2 clinical development, with studies evaluating its efficacy and safety compared to insulin glargine in insulin-naïve patients with type 2 diabetes who are treated with metformin alone or in combination with SGLT2 inhibitors. The drug is administered as a subcutaneous injection, and early-phase trials have focused on assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and patients with type 2 diabetes. The precise mechanism of action has not been disclosed publicly; however, based on the context of use (as a comparator to basal insulin), it may act as a novel long-acting glucose-lowering agent[1][3][4][7].